X

Trial Profile

Dendritic Cells loaded with allogeneic tumor lysate (MesoPher) in combination with a CD40 agonist (Mitazalimab) for metastatic pancreatic disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Oct 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous dendritic cell vaccine Amphera (Primary) ; Autologous dendritic cell vaccine Amphera (Primary) ; Mitazalimab (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions
Acronyms REACtiVe-2

Most Recent Events

11 Oct 2023 Status changed from recruiting to completed.
27 Apr 2023 According to an Alligator Bioscience AB media release, company today announce the successful dosing of the last patient in this trial.
27 Apr 2023 According to an Alligator Bioscience AB media release, preliminary results of this trial are expected in Q4 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com